Preview data. Company signal currently comes from paper + trial co-mentions only. Patent, SEC, and news ingestion lands in Phase M — numbers shown are representative seed fixtures until then.

Mindshare

Company Mindshare

Who's dominating the AI drug-discovery conversation this quarter — and who's quietly rising.

Share of voice · last 7 days

Company Mindshare

Size = share · Colour = 7d momentum

Source: SEC filings, press releases, Twitter/X, Endpoints, BioPharma Dive · biotech.today analysis

Leaderboard

#CompanyAttention7d ΔSources
SourcesTwitterPapersNewsPodcasts

Mindshare by modality

Of the attention within each modality, which AI-native companies are capturing it. Companies cluster on the modalities they’ve publicly committed to.

ModalityShare
Isomorphic LabsRecursionArvinasRelay TherapeuticsInsitroXairaInsilico MedicineSchrödingerAtomwiseExscientia
PROTAC
34%
14%
12%
10%
8%
7%
6%
ADC
21%
18%
14%
12%
11%
9%
6%
mRNA
24%
18%
14%
11%
10%
8%
7%
Gene therapy
28%
20%
16%
12%
8%
6%
Cell therapy
22%
19%
14%
12%
11%
9%
7%
Small molecule
22%
18%
14%
12%
11%
9%
6%
0%20%40%60%80%100%

Source: Company press releases, clinical trial sponsors, conference talks · biotech.today analysis

Breakdown

By Stage

(5)
  • Public612
  • Series D+392
  • Series C244
  • Series B182
  • Series A / seed114

By Modality

(5)
  • Small molecule1,024
  • Antibody / biologics641
  • Gene / cell388
  • mRNA / vaccine212
  • Platform-only147

By Geography

(6)
  • United States1,108
  • United Kingdom344
  • Switzerland286
  • Denmark121
  • Germany108
  • China94